EA201070713A1 - Твердые лекарственные формы - Google Patents

Твердые лекарственные формы

Info

Publication number
EA201070713A1
EA201070713A1 EA201070713A EA201070713A EA201070713A1 EA 201070713 A1 EA201070713 A1 EA 201070713A1 EA 201070713 A EA201070713 A EA 201070713A EA 201070713 A EA201070713 A EA 201070713A EA 201070713 A1 EA201070713 A1 EA 201070713A1
Authority
EA
Eurasian Patent Office
Prior art keywords
androstan
ethynyl
solid
diol
formulations
Prior art date
Application number
EA201070713A
Other languages
English (en)
Other versions
EA018974B1 (ru
EA018974B9 (ru
Inventor
Стивен К. Вайт
Двайт Стикни
Эрин Олсон
Кейт Р. Лоример
Брентон С. Вулф
Original Assignee
Харбор Биосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Харбор Биосайенсиз, Инк. filed Critical Харбор Биосайенсиз, Инк.
Publication of EA201070713A1 publication Critical patent/EA201070713A1/ru
Publication of EA018974B1 publication Critical patent/EA018974B1/ru
Publication of EA018974B9 publication Critical patent/EA018974B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

В изобретении предложен и описан твердый 17α-этинил-5α-андростан-3α,17β-диол, в том числе, его аморфные и кристаллические формы и конкретные полиморфные формы. Ангидриды и сольваты 17α-этинил-5α-андростан-3α,17β-диола включают ангидрид в форме III и сольват в форме I. Изобретение также относится к твердым и суспензионным составам, содержащим 17α-этинил-5α-андростан-3α,17β-диол в описанной твердой форме, и применению этих составов для лечения у субъектов или пациентов-людей раков или предраковых состояний, таких как рак предстательной железы или рак молочной железы. Изобретение также относится к способам получения жидких составов из твердых форм 17α-этинил-5α-андростан-3α,17β-диола и применению таких составов при лечении описанных состояний.
EA201070713A 2008-02-05 2009-02-05 Твердые лекарственные формы EA018974B9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2647208P 2008-02-05 2008-02-05
US9369408P 2008-09-02 2008-09-02
PCT/US2009/033280 WO2009100258A1 (en) 2008-02-05 2009-02-05 Pharmaceutical solid state forms

Publications (3)

Publication Number Publication Date
EA201070713A1 true EA201070713A1 (ru) 2011-08-30
EA018974B1 EA018974B1 (ru) 2013-12-30
EA018974B9 EA018974B9 (ru) 2014-04-30

Family

ID=40952461

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070713A EA018974B9 (ru) 2008-02-05 2009-02-05 Твердые лекарственные формы

Country Status (11)

Country Link
US (4) US8518922B2 (ru)
EP (1) EP2249838A4 (ru)
JP (1) JP2011511011A (ru)
KR (1) KR20100113602A (ru)
CN (2) CN103467554A (ru)
AU (1) AU2009212314C1 (ru)
CA (1) CA2712005C (ru)
EA (1) EA018974B9 (ru)
HK (1) HK1147695A1 (ru)
IL (1) IL207378A0 (ru)
WO (1) WO2009100258A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910156B (zh) 2007-12-07 2013-12-04 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式
AU2009231589B2 (en) * 2008-04-03 2013-11-07 Neurmedix, Inc. Solid state forms of a pharmaceutical
CA2782266A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
AU2011205230A1 (en) 2010-01-13 2012-08-02 Caris Life Sciences Switzerland Holdings Gmbh Detection of gastrointestinal disorders
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
WO2012083161A1 (en) * 2010-12-17 2012-06-21 Harbor Biosciences, Inc. Steroid tetrol solid state forms
CN104173353B (zh) * 2013-05-22 2018-08-21 中国医药工业研究总院 不含表面活性剂的固体制剂及其制备方法
US10231932B2 (en) * 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
US10786461B2 (en) 2014-11-17 2020-09-29 Context Biopharma Inc. Onapristone extended-release compositions and methods
BR112018005999A2 (pt) 2015-09-25 2019-01-08 Context Biopharma Inc métodos para a produção de intermediários de onapristona
KR20180113988A (ko) 2015-12-15 2018-10-17 컨텍스트 바이오파마 인코포레이티드 비정질 오나프리스톤 조성물 및 그 제조방법
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
RU2019133577A (ru) * 2017-03-30 2021-04-30 Мерк Патент Гмбх ТВЕРДАЯ ФОРМА (S)-[2-хлор-4-фтор-5-(7-морфолин-4-илхиназолин-4-ил)фенил]-(6-метокси-пиридазин-3-ил)метанола
RU2668526C1 (ru) * 2017-08-18 2018-10-01 Федеральное государственное бюджетное учреждение "Информационно-методический центр по экспертизе, учету и анализу обращения средств медицинского применения" Федеральной службы по надзору в сфере здравоохранения Способ идентификации и последующего количественного определения основных компонентов в инъекционных лекарственных средствах
EP3888021B1 (en) 2018-11-30 2024-02-21 Caris MPI, Inc. Next-generation molecular profiling
CN111773388B (zh) * 2019-04-04 2023-07-18 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
CA3163319A1 (en) 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE681869C (de) * 1935-11-22 1939-10-03 Schering Ag Verfahren zur Darstellung von tertiaeren Alkoholen der Cyclopentanopolyhydrophenanthrenreihe
CH202847A (de) 1937-06-26 1939-02-15 Chem Ind Basel Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe.
EP0614456B1 (en) 1992-08-28 1999-06-09 Bone Care International, Inc. 1alpha,24(s)-dihydroxy vitamin d2, its formation and use
US5567830A (en) * 1994-02-14 1996-10-22 Cocensys, Inc. Process for synthesis of acetylenic carbinols
CA2250347C (en) 1996-03-29 2006-02-21 Duphar International Research B.V. Piperazine and piperidine compounds with high affinity for dopamine-d2 and serotonin-5ht1a receptors
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
US7045513B1 (en) 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
AU7736300A (en) 1999-09-30 2001-04-30 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
ES2253451T3 (es) 2000-12-14 2006-06-01 Ortho-Mcneil Pharmaceutical, Inc. Productos a base de hormona esteroide y sus procedimientos de fabricacion.
AR034206A1 (es) 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
US7540016B2 (en) * 2004-07-21 2009-05-26 Beachhead Solutions, Inc. System and method for lost data destruction of electronic data stored on a portable electronic device which communicates with servers that are inside of and outside of a firewall
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
TW200730505A (en) * 2005-12-07 2007-08-16 Merck & Co Inc Polymorphs of an androgen receptor modulator
TWI305979B (en) * 2006-03-24 2009-02-01 Hon Hai Prec Ind Co Ltd Wireless transceiving system
DK2486924T3 (en) * 2006-04-22 2019-03-04 Neurmedix Inc Medicines and uses
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Also Published As

Publication number Publication date
CN101939009A (zh) 2011-01-05
AU2009212314A1 (en) 2009-08-13
WO2009100258A1 (en) 2009-08-13
CA2712005C (en) 2014-04-15
CN101939009B (zh) 2013-07-17
US20130345184A1 (en) 2013-12-26
US20130345455A1 (en) 2013-12-26
AU2009212314C1 (en) 2014-05-08
US20090291932A1 (en) 2009-11-26
CA2712005A1 (en) 2009-08-13
JP2011511011A (ja) 2011-04-07
AU2009212314B2 (en) 2013-11-21
US20130338125A1 (en) 2013-12-19
HK1147695A1 (en) 2011-08-19
CN103467554A (zh) 2013-12-25
EA018974B1 (ru) 2013-12-30
EP2249838A4 (en) 2012-05-02
EP2249838A1 (en) 2010-11-17
EA018974B9 (ru) 2014-04-30
US8518922B2 (en) 2013-08-27
IL207378A0 (en) 2010-12-30
KR20100113602A (ko) 2010-10-21
US9314471B2 (en) 2016-04-19

Similar Documents

Publication Publication Date Title
EA201070713A1 (ru) Твердые лекарственные формы
PH12019501792A1 (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
JO2787B1 (en) Alternative amide derivatives and methods of use
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
MX2012007367A (es) Compuestos substituidos de imidazopiridinilo-aminopiridina.
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
MX2009000531A (es) Derivados heterociclicos fusionados y metodos de uso.
MX2021001494A (es) Anticuerpos dkk1 y metodos de uso.
MY162502A (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
MY153263A (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
MY160075A (en) Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
EA201071250A1 (ru) Композиции и методы для лечения рака молочной железы
SG171583A1 (en) Composition for the treatment of resistant cancers comprising oridonin
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
MX2018001965A (es) Formulaciones liquidas que contienen picosulfato y citrato de magnesio.
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
EP2528440A4 (en) SUBSTITUTED NORINDEN ISOCHINOLINE, SYNTHESIS THEREOF AND METHOD OF USE THEREOF
EP2124554A4 (en) COMPOSITIONS AND METHODS FOR CANCER TREATMENT
EP2073635A4 (en) MACROCYCLIC SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU